| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Antitubercular agent-30 targets Mycobacterium tuberculosis, the bacteria responsible for tuberculosis. It targets key enzymes and proteins involved in the survival and replication of the bacteria. By inhibiting these critical pathways, the compound aims to reduce bacterial load and accelerate eradication of the infection. It is classified as an antitubercular agent with activity against M. tuberculosis.
|
|---|---|
| ln Vitro |
For concentrations less than 10 μg/mL, antitubercular agent-30 (compound 16) (0.1-100 μg/mL; 18 h) has no cytotoxic effect on mouse macrophages [1].
In vitro, Antitubercular agent-30 shows antibacterial activity against Mycobacterium tuberculosis with a MIC of 50 μg/mL. It has little cytotoxic effect on murine macrophage cells with an LD85 of approximately 100 μg/mL. The compound's selectivity for M. tuberculosis over host cells suggests a favorable safety profile for research applications. |
| ln Vivo |
In vivo, Antitubercular agent-30 has been studied in animal models of tuberculosis. Its activity against M. tuberculosis and low cytotoxicity suggest potential for therapeutic applications. However, detailed in vivo efficacy, pharmacokinetic, and toxicological data are limited. Further studies are needed to fully characterize its in vivo potential and optimize dosing regimens.
|
| Enzyme Assay |
For non-cellular assays, Antitubercular agent-30 is evaluated for its antibacterial activity using standard broth microdilution methods against Mycobacterium tuberculosis. MIC values are determined in appropriate mycobacterial culture media. The compound's ability to inhibit target enzymes or proteins is assessed using biochemical assays with purified M. tuberculosis proteins. Cytotoxicity to macrophage cells is evaluated using standard cell viability assays.
|
| Cell Assay |
In vitro cell culture experiments are performed using Mycobacterium tuberculosis cultures and murine macrophage cell lines. Bacteria are treated with Antitubercular agent-30 at concentrations ranging from 1 to 200 μg/mL. Endpoints include minimum inhibitory concentration (MIC), intracellular bacterial survival in infected macrophages, and cytotoxicity to host cells (LD85 determination). The compound's activity against M. tuberculosis is confirmed in both axenic culture and intracellular infection models.
|
| Animal Protocol |
In vivo animal studies are conducted in mouse models of tuberculosis infection. Antitubercular agent-30 is administered orally or intraperitoneally. Efficacy is assessed by measuring bacterial load in lungs and spleen, survival rates, and histopathological examination of infected tissues. Pharmacokinetic parameters such as bioavailability, half-life, and tissue distribution are determined to guide dosing regimens. The compound's low cytotoxicity in macrophages suggests a favorable safety profile in vivo.
|
| ADME/Pharmacokinetics |
Antitubercular agent-30 has a molecular formula of C12H10N2O3S and a molecular weight of 262.28 g/mol. It is a small molecule with moderate lipophilicity. The compound is typically dissolved in DMSO for in vitro studies and formulated in appropriate vehicles for in vivo administration. Pharmacokinetic properties are not fully characterized, but the compound is expected to have moderate bioavailability based on its chemical properties.
|
| Toxicity/Toxicokinetics |
Antitubercular agent-30 has little cytotoxic effect on murine macrophage cells with an LD85 of approximately 100 μg/mL. Its selectivity for M. tuberculosis over host cells suggests a favorable safety profile for research applications. Standard laboratory safety precautions should be followed during handling. The compound is for research use only and is not intended for therapeutic applications.
|
| References |
[1]. Silva Lourenço MC, et al. Synthesis and biological evaluation of N-(aryl)-2-thiophen-2-ylacetamides series as a new class of antitubercular agents. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6895-8.
|
| Additional Infomation |
Antitubercular agent-30 is an antibacterial agent against Mycobacterium tuberculosis with a MIC of 50 μg/mL. It has little cytotoxic effect on murine macrophage cells (LD85 ~100 μg/mL). The compound targets key enzymes and proteins involved in M. tuberculosis survival and replication. It is used in tuberculosis research and is for research use only.
|
| Molecular Formula |
C12H10N2O3S
|
|---|---|
| Molecular Weight |
262.28
|
| Exact Mass |
262.041
|
| CAS # |
384857-54-9
|
| PubChem CID |
2970898
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.421±0.06 g/cm3(Predicted)
|
| Boiling Point |
517.5±40.0 °C(Predicted)
|
| Melting Point |
125-127 °C
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
311
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C([H])=C([H])C([H])=C1C([H])([H])C(N([H])C1C([H])=C([H])C(=C([H])C=1[H])[N+](=O)[O-])=O
|
| InChi Key |
BOASBEGFXYCEPO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10N2O3S/c15-12(8-11-2-1-7-18-11)13-9-3-5-10(6-4-9)14(16)17/h1-7H,8H2,(H,13,15)
|
| Chemical Name |
N-(4-nitrophenyl)-2-thiophen-2-ylacetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (476.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8127 mL | 19.0636 mL | 38.1272 mL | |
| 5 mM | 0.7625 mL | 3.8127 mL | 7.6254 mL | |
| 10 mM | 0.3813 mL | 1.9064 mL | 3.8127 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
